

SAMPLE CODING

First-line Metastatic Breast Cancer

Codes below may apply to your patient

| TYPE | CODE | | DESCRIPTION |
|--|---|---------------|---|
| Diagnosis: ICD-10-CM Primary Breast Cancer Site* | C50.011–C50.019 C50.111–C50.119 C50.211–C50.219 C50.311–C50.319 C50.411–C50.419 C50.511–C50.519 C50.611–C50.619 C50.811–C50.819 C50.911–C50.919 | | Malignant neoplasm of the female breast |
| | C50.021–C50.029 C50.121–C50.129 C50.221–C50.229 C50.321–C50.329 C50.421–C50.429 C50.521–C50.529 C50.621–C50.629 C50.821–C50.829 C50.921–C50.929 | | Malignant neoplasm of the male breast |
| Additional Diagnosis Code: Estrogen Receptor Status* | Z17.0 | | Hormone Receptor Positivity |
| Drug: NDC Note: Payer requirements regarding use of a 10-digit or 11-digit NDC may vary. Both formats are listed here for your reference. | 10-digit | 11-digit | |
| | 50242-084-08 | 50242-0084-08 | 3-mg film-coated tablets, 28-count bottle |
| | 50242-079-08 | 50242-0079-08 | 9-mg film-coated tablets, 28-count bottle |

ICD-10-CM=International Classification of Diseases, 10th Revision, Clinical Modification; NDC=National Drug Code.

*Use all codes relevant to your patient. Individual payers may have different preferences for billing Itovebi. Check with your local payers for specific information.

These codes are not all-inclusive; appropriate codes can vary by patient, setting of care and payer. Correct coding is the responsibility of the provider submitting the claim for the item or service. Please check with the payer to verify codes and special billing requirements. Genentech does not make any representation or guarantee concerning reimbursement or coverage for any item or service.

Many payers will not accept unspecified codes. If you use an unspecified code, please check with your payer.

Itovebi[™] is a trademark of Genentech, Inc.

Please see full [Prescribing Information](#) for Important Safety Information.